Capital markets day at the Royal Swedish Academy of Engineering Sciences IVA in Stockholm

David welcomes

Mårten presents

Kristine presents

Look at all presentations from IVA here

PRESSRELEASES

11 June, 2024

First patient dosed in Nanexa’s Phase I trial of NEX-22 in type 2 diabetes

Nanexa AB today announces that the company’s Phase 1 study for type 2 diabetes has been initiated with dosing of the first patient. The study evaluates a long-acting depot formulation of the GLP-1 analog liraglutide with Nanexa’s patented PharmaShell® system within the NEX-22 project. The study is a dose-escalation study aimed at evaluating the pharmacokinetic profile, safety and tolerability of different doses.

READ MORE

15 May, 2024

Bulletin from Nanexa’s Annual General Meeting

The Annual General Meeting (AGM) of Nanexa AB (publ) has been held on May 15, 2024, at which meeting submitted proposals were passed. The complete proposals for resolutions are set out in the AGM notice.

READ MORE

LATEST REPORTS

PRESENTATIONS

2024-05-23

Redeye Diabetes Event

2024-05-22

Nanexa – Investor Days May 22-23

2024-03-08

ABG Sundal Collier – Fireside chat with CEO David Westberg

MEET NANEXA

Inga planerade träffar

PRENUMERERA